Validation of the acenocoumarol EU-PACT algorithms: Similar performance in the Rotterdam Study cohort as in the original study

Pharmacogenomics

Volumn 13, Issue 11, 2012, Pages 1239-1245

  Van Schie, Rianne M F ^a   El Khedr, Nadia ^a   Verhoef, Talitha I ^a   Teichert, Martina ^a   Stricker, Bruno H ^a   Hofman, Albert ^a   Buhre, Peter N ^a   Wessels, Judith A M ^a   Schalekamp, Tom ^a   Le Cessie, Saskia ^a   Van Der Meer, Felix J M ^a   Rosendaal, Frits R ^a   De Boer, Anthonius ^a   Maitland Van Der Zee, Anke Hilse ^a   Visser, Loes E ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

acenocoumarol; CYP2C9; dose algorithm; validation; VKORC1

Indexed keywords

ACENOCOUMAROL;

ADULT; AGED; ALGORITHM; ANTICOAGULANT THERAPY; ARTICLE; COHORT ANALYSIS; COMPUTER PREDICTION; CYP2C9 GENE; DOSE CALCULATION; FEMALE; GENE; GENOTYPE; GENOTYPE GUIDED DOSE ALGORITHM; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PHARMACOGENOMICS; VALIDATION PROCESS; VKORC1 GENE;

ACENOCOUMAROL; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; PHENPROCOUMON; POLYMORPHISM, SINGLE NUCLEOTIDE; WARFARIN;

EID: 84865478935     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.101     Document Type: Article

References (30)

1. Rosendaal FR. The Scylla and Charybdis of oral anticoagulant treatment. N. Engl. J. Med. 335(8), 587-589 (1996). (Pubitemid 26272315)
2. James AH, Britt RP, Raskino CL, Thompson SG. Factors affecting the maintenance dose of warfarin. J. Clin. Pathol. 45(8), 704-706 (1992).
3. van der Hooft CS, Sturkenboom MC, van Grootheest K, Kingma HJ, Stricker BH. Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands. Drug Saf. 29(2), 161-168 (2006). (Pubitemid 43213889)
4. Schneeweiss S, Hasford J, Gottler M, Hoffmann A, Riethling AK, Avorn J. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur. J. Clin. Pharmacol. 58(4), 285-291 (2002). (Pubitemid 34827858)
5. Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Ann. Intern. Med. 147(11), 755-765 (2007). (Pubitemid 351664440)
6. Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch. Intern. Med. 168(17), 1890-1896 (2008).
7. Penning-van Beest FJA, van Meegen E, Rosendaal FR, Stricker BHC. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb. Haemost. 86(2), 569-574 (2001). (Pubitemid 32743268)
8. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N. Engl. J. Med. 335(8), 540-546 (1996). (Pubitemid 26272308)
9. Becquemont L. Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice. Eur. J. Clin. Pharmacol. 64(10), 953-960 (2008).
10. Gage BF, Eby C, Johnson JA et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3), 326-331 (2008).
11. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009).
12. Lenzini P, Wadelius M, Kimmel S et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin. Pharmacol. Ther. 87(5), 572-578 (2010).
13. Sconce EA, Khan TI, Wynne HA et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106(7), 2329-2333 (2005). (Pubitemid 41510803)
14. Wadelius M, Chen LY, Lindh JD et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4), 784-792 (2009).
15. van Schie RMF, Wessels JA, le Cessie S et al. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur. Heart J. 32(15), 1909-1917 (2011).
16. Markatos CN, Grouzi E, Politou M et al. VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients. Pharmacogenomics 9(11), 1631-1638 (2008).
17. Geisen C, Luxembourg B, Watzka M et al. Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters. Eur. J. Clin. Pharmacol. 67(4), 371-381 (2010).
18. Schalekamp T, Brasse BP, Roijers JFM et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin. Pharmacol. Ther. 80(1), 13-22 (2006). (Pubitemid 43964915)
19. Schalekamp T, Brasse BP, Roijers JFM et al. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin. Pharmacol. Ther. 81(2), 185-193 (2007). (Pubitemid 46174815)
20. van Schie RMF, Wadelius MI, Kamali F et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 10(10), 1687-1695 (2009).
21. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur. J. Epidemiol. 7(4), 403-422 (1991).
22. Hofman A, Breteler MM, van Duijn CM et al. The Rotterdam Study: objectives and design update. Eur. J. Epidemiol. 22(11), 819-829 (2007). (Pubitemid 350105372)
23. Leening MJ, Kavousi M, Heeringa J et al. Methods of data collection and definitions of cardiac outcomes in the Rotterdam Study. Eur. J. Epidemiol. 27(3), 173-185 (2012).
24. Teichert M, van Schaik RH, Hofman A et al. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. Clin. Pharmacol. Ther. 85(4), 379-386 (2009).
25. Visser LE, van Vliet M, van Schaik RH et al. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 14(1), 27-33 (2004).
26. Aynacioglu AS, Brockmoller J, Bauer S et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br. J. Clin. Pharmacol. 48(3), 409-415 (1999). (Pubitemid 29417726)
27. Limdi NA, Wadelius M, Cavallari L et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115(18), 3827-3834 (2010).
28. Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadee W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 112(4), 1013-1021 (2008).
29. Stolk L, van Meurs JB, Arp PP, Hofman A, Pols HA, Uitterlinden AG. The RIZ Pro704 insertion-deletion polymorphism, bone mineral density and fracture risk: the Rotterdam Study. Bone 42(2), 286-293 (2008).
30. Ansell J, Hollowell J, Pengo V, Martinez-Brotons F, Caro J, Drouet L. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J. Thromb. Thrombolysis 23(2), 83-91 (2007). (Pubitemid 46416852)